AI Article Synopsis

  • Protein aggregates can serve as reservoirs that release active precursor proteins, suggesting their potential as functional vaccine delivery systems to enhance immune responses.
  • The study examines aggregated Ag85B as a prophylactic vaccine, showing it can provide sustained antigen release and effectively activate immune cells, resulting in a strong Th1-dominant response in mice.
  • Immunization with aggregated Ag85B produced antibodies that recognize both the native and monomeric forms of the protein, offering vaccine efficacy comparable to the established BCG vaccine, highlighting its potential against intracellular pathogens.

Article Abstract

Protein aggregates have been reported to act as a reservoir that can release biologically active, native form of precursor protein. Keeping this fact into consideration, it is tempting to exploit protein aggregate-based antigen delivery system as a functional vaccine to expand desirable immunological response in the host. Herein, we explored the capacity of aggregated Ag85B of () to act as a prophylactic vaccine system that releases the precursor antigen in slow and sustained manner. Being particulate system with exposed hydrophobic residues, aggregated Ag85B is likely to be avidly taken up by both phagocytosis as well as fusion with plasma membrane of antigen presenting cells, leading to its direct delivery to their cytosol. Its unique ability to access cytosol of target cells is further evident from the fact that immunization with aggregated Ag85B led to the induction of Th1-dominant immune response along with upregulated expression of qualitatively superior polyfunctional T cells in the mice. Antibodies generated following immunization with aggregated antigen recognized both native and monomeric Ag85B released from protein aggregate. The implicated immunization strategy offers protection at par to that of established BCG vaccine with desirable central and effector memory responses against subsequent aerosol challenge. The study highlights the potential of aggregated Ag85B as promising antigen delivery system and paves the way to design better prophylactic regimes against various intracellular pathogens including .

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5711810PMC
http://dx.doi.org/10.3389/fimmu.2017.01608DOI Listing

Publication Analysis

Top Keywords

aggregated ag85b
20
antigen delivery
8
delivery system
8
immunization aggregated
8
ag85b
6
antigen
6
aggregated
5
evaluation aggregated
4
ag85b antigen
4
antigen biophysical
4

Similar Publications

Article Synopsis
  • Protein aggregates can serve as reservoirs that release active precursor proteins, suggesting their potential as functional vaccine delivery systems to enhance immune responses.
  • The study examines aggregated Ag85B as a prophylactic vaccine, showing it can provide sustained antigen release and effectively activate immune cells, resulting in a strong Th1-dominant response in mice.
  • Immunization with aggregated Ag85B produced antibodies that recognize both the native and monomeric forms of the protein, offering vaccine efficacy comparable to the established BCG vaccine, highlighting its potential against intracellular pathogens.
View Article and Find Full Text PDF

Doubly Phosphorylated Peptide Vaccines to Protect Transgenic P301S Mice against Alzheimer's Disease Like Tau Aggregation.

Vaccines (Basel)

July 2014

Institute of Bioanalytical Chemistry, Faculty of Chemistry and Mineralogy, Universität Leipzig, Deutscher Platz 5, Leipzig 04103, Germany.

Intracellular neurofibrillary tangles and extracellular senile plaques are potential targets for active and passive immunotherapies. In this study we used the transgenic mouse model P301S for active immunizations with peptide vaccines composed of a double phosphorylated tau neoepitope (pSer202/pThr205, pThr212/pSer214, pThr231/pSer235) and an immunomodulatory T cell epitope from the tetanus toxin or tuberculosis antigen Ag85B. Importantly, the designed vaccine combining Alzheimer's disease (AD) specific B cell epitopes with foreign (bacterial) T cell epitopes induced fast immune responses with high IgG₁ titers after prophylactic immunization that subsequently decreased over the observation period.

View Article and Find Full Text PDF

The adjuvant efficacy of cationic liposomes composed of dimethyldioctadecylammonium bromide and trehalose dibehenate (DDA:TDB) is well established. Whilst the mechanism behind its immunostimulatory action is not fully understood, the ability of the formulation to promote a 'depot effect' is a consideration. The depot effect has been suggested to be primarily due to their cationic nature which results in electrostatic adsorption of the antigen and aggregation of the vesicles at the site of injection.

View Article and Find Full Text PDF

To develop novel delivery system for tuberculosis (TB) subunit vaccine, biodegradable chitosan microspheres were prepared and used to deliver a fusion protein, Ag85B-MPT64(190-198)-Mtb8.4 (AMM for short), made from three Mycobacterium tuberculosis genes. AMM-loaded microspheres were first characterized for their morphology, size, zeta potential, loading efficiency, and in vitro release of AMM.

View Article and Find Full Text PDF

Vesicular adjuvant systems composing dimethyldioctadecylammonium (DDA) can promote both cell-mediated and humoral immune responses to the tuberculosis vaccine fusion protein in mice. However, these DDA preparations were found to be physically unstable, forming aggregates under ambient storage conditions. Therefore there is a need to improve the stability of such systems without undermining their potent adjuvanticity.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!